These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 24625530

  • 1. Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana.
    Kasonde M, Niska RW, Rose C, Henderson FL, Segolodi TM, Turner K, Smith DK, Thigpen MC, Paxton LA.
    PLoS One; 2014; 9(3):e90111. PubMed ID: 24625530
    [Abstract] [Full Text] [Related]

  • 2. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
    Mulligan K, Glidden DV, Anderson PL, Liu A, McMahan V, Gonzales P, Ramirez-Cardich ME, Namwongprom S, Chodacki P, de Mendonca LM, Wang F, Lama JR, Chariyalertsak S, Guanira JV, Buchbinder S, Bekker LG, Schechter M, Veloso VG, Grant RM, Preexposure Prophylaxis Initiative Study Team.
    Clin Infect Dis; 2015 Aug 15; 61(4):572-80. PubMed ID: 25908682
    [Abstract] [Full Text] [Related]

  • 3. Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.
    Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM.
    J Acquir Immune Defic Syndr; 2017 Oct 01; 76(2):177-182. PubMed ID: 28639995
    [Abstract] [Full Text] [Related]

  • 4. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.
    Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Liu N, Wilson CM, Hazra R, Hosek SG, Anderson PL, Seifert SM, Kapogiannis BG, Mulligan K, Adolescent Medicine Trials Network for HIV/AIDS Interventions 117 study team.
    Clin Infect Dis; 2017 Feb 01; 64(3):317-325. PubMed ID: 28013265
    [Abstract] [Full Text] [Related]

  • 5. Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis.
    Mirembe BG, Kelly CW, Mgodi N, Greenspan S, Dai JY, Mayo A, Piper J, Akello CA, Kiweewa FM, Magure T, Nakabiito C, Marrazzo JM, Chirenje ZM, Riddler SA, MTN-003B Protocol Team.
    J Acquir Immune Defic Syndr; 2016 Mar 01; 71(3):287-94. PubMed ID: 26866954
    [Abstract] [Full Text] [Related]

  • 6. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco.
    Liu AY, Vittinghoff E, Sellmeyer DE, Irvin R, Mulligan K, Mayer K, Thompson M, Grant R, Pathak S, O'Hara B, Gvetadze R, Chillag K, Grohskopf L, Buchbinder SP.
    PLoS One; 2011 Mar 01; 6(8):e23688. PubMed ID: 21897852
    [Abstract] [Full Text] [Related]

  • 7. Effects of vitamin D and calcium supplementation on bone mineral density among Thai youth using daily HIV pre-exposure prophylaxis.
    Pornpaisalsakul K, Songtaweesin WN, Tepmongkol S, Wongharn P, Kawichai S, Suponsilchai V, Anugulruengkitt S, Puthanakit T, CE-PID - IHRI Adolescent Study Team.
    J Int AIDS Soc; 2020 Oct 01; 23(10):e25624. PubMed ID: 33040465
    [Abstract] [Full Text] [Related]

  • 8. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
    Mugwanya KK, Wyatt C, Celum C, Donnell D, Mugo NR, Tappero J, Kiarie J, Ronald A, Baeten JM, Partners PrEP Study Team.
    JAMA Intern Med; 2015 Feb 01; 175(2):246-54. PubMed ID: 25531343
    [Abstract] [Full Text] [Related]

  • 9. Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine.
    Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM.
    Clin Infect Dis; 2018 Jul 18; 67(3):411-419. PubMed ID: 29415175
    [Abstract] [Full Text] [Related]

  • 10. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
    Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, Henderson FL, Pathak SR, Soud FA, Chillag KL, Mutanhaurwa R, Chirwa LI, Kasonde M, Abebe D, Buliva E, Gvetadze RJ, Johnson S, Sukalac T, Thomas VT, Hart C, Johnson JA, Malotte CK, Hendrix CW, Brooks JT, TDF2 Study Group.
    N Engl J Med; 2012 Aug 02; 367(5):423-34. PubMed ID: 22784038
    [Abstract] [Full Text] [Related]

  • 11. HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial.
    Wohl DA, Spinner CD, Flamm J, Hare CB, Doblecki-Lewis S, Ruane PJ, Molina JM, Mills A, Brinson C, Ramgopal M, Clarke A, Crofoot G, Martorell C, Carter C, Cox S, Hojilla JC, Shao Y, Das M, Kintu A, Baeten JM, Grant RM, Mounzer K, Mayer K.
    Lancet HIV; 2024 Aug 02; 11(8):e508-e521. PubMed ID: 39008999
    [Abstract] [Full Text] [Related]

  • 12. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
    Vincent KL, Moss JA, Marzinke MA, Hendrix CW, Anton PA, Pyles RB, Guthrie KM, Dawson L, Olive TJ, Butkyavichene I, Churchman SA, Cortez JM, Fanter R, Gunawardana M, Miller CS, Yang F, Rosen RK, Vargas SE, Baum MM.
    PLoS Med; 2018 Sep 02; 15(9):e1002655. PubMed ID: 30265679
    [Abstract] [Full Text] [Related]

  • 13. Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project.
    Tang EC, Vittinghoff E, Anderson PL, Cohen SE, Doblecki-Lewis S, Bacon O, Coleman ME, Buchbinder SP, Chege W, Kolber MA, Elion R, Shlipak M, Liu AY.
    J Acquir Immune Defic Syndr; 2018 Feb 01; 77(2):193-198. PubMed ID: 28991887
    [Abstract] [Full Text] [Related]

  • 14. Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals.
    Jotwani V, Scherzer R, Glidden DV, Mehrotra M, Defechereux P, Liu A, Gandhi M, Bennett M, Coca SG, Parikh CR, Grant RM, Shlipak MG.
    J Acquir Immune Defic Syndr; 2018 Jun 01; 78(2):169-174. PubMed ID: 29767638
    [Abstract] [Full Text] [Related]

  • 15. Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate - emtricitabine for HIV pre-exposure prophylaxis.
    Liegeon G, Antoni G, Pialoux G, Capitant C, Cotte L, Charreau I, Tremblay C, Cua E, Senneville E, Raffi F, Meyer L, Molina JM, ANRS-IPERGAY study group.
    J Int AIDS Soc; 2020 Feb 01; 23(2):e25420. PubMed ID: 32086878
    [Abstract] [Full Text] [Related]

  • 16. Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men.
    Shieh E, Marzinke MA, Fuchs EJ, Hamlin A, Bakshi R, Aung W, Breakey J, Poteat T, Brown T, Bumpus NN, Hendrix CW.
    J Int AIDS Soc; 2019 Nov 01; 22(11):e25405. PubMed ID: 31692269
    [Abstract] [Full Text] [Related]

  • 17. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.
    McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, Myers L, Melbourne K, Ha B, Sax PE.
    J Infect Dis; 2011 Jun 15; 203(12):1791-801. PubMed ID: 21606537
    [Abstract] [Full Text] [Related]

  • 18. Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone.
    Havens PL, Long D, Schuster GU, Gordon CM, Price G, Wilson CM, Kapogiannis BG, Mulligan K, Stephensen CB, Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 117 and 109 study teams.
    Antivir Ther; 2018 Jun 15; 23(7):623-628. PubMed ID: 30260797
    [Abstract] [Full Text] [Related]

  • 19. Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women.
    Mugwanya K, Baeten J, Celum C, Donnell D, Nickolas T, Mugo N, Branch A, Tappero J, Kiarie J, Ronald A, Yin M, Wyatt C, Partners PrEP Study Team.
    J Infect Dis; 2016 Oct 01; 214(7):1050-7. PubMed ID: 27029778
    [Abstract] [Full Text] [Related]

  • 20. Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV.
    Klassen KM, Kimlin MG, Fairley CK, Emery S, Anderson PH, Ebeling PR, STEAL Study Group.
    Osteoporos Int; 2016 May 01; 27(5):1737-45. PubMed ID: 26659069
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.